Article

Sling shows higher overall success, patient satisfaction than Burch

Two-year results of the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr) will allow physicians and patients to have more educated conversations about procedures for stress urinary incontinence and what can be expected in terms of efficacy and complications, according to the investigators of that prospective, randomized, National Institute of Diabetes and Digestive and Kidney Diseases-supported trial.

Related Videos
Illustration of prostate | Image Credit: © Judith - stock.adobe.com
Medcast series
Related Content
Identifying unique therapeutic targets for chromophobe kidney cancer
March 6th 2025

Identifying unique therapeutic targets for chromophobe kidney cancer

David A. Braun, MD, PhD Hannah Clarke
“What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Study links poor semen quality with shorter life span
March 5th 2025

Study links poor semen quality with shorter life span

Hannah Clarke
The average life expectancy was 80.3 years among men with a total motile sperm count over 120 million, compared with 77.6 years among men with a total motile sperm count ranging from >0 to 5 million.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
March 4th 2025

UTUC roundtables: Grade and location drive care

Urology Times staff
In 2 recent case-based roundtable discussions, experts tackled diagnosis and treatment strategy for upper tract urothelial carcinoma.
Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
March 4th 2025

Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC

Hannah Clarke
The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.
© 2025 MJH Life Sciences

All rights reserved.